University of Vermont

College of Medicine

Department of Neurological Sciences

Bio for Angela Applebee, M.D.
Angela Applebee, M.D.

Angela Applebee, M.D.

Associate Professor
Department of Neurological Sciences


Contact Information
E-mail: angela.applebee@uvm.edu
Phone:
802-847-4589
Office Location:
University of Vermont College of Medicine, 1 So. Prospect Street, UHC - Arnold 2, Burlington, VT 05401

Education

1998-2002:  M.D., University of South Dakota School of Medicine, Vermillion, SD
1994-1998:  B.A., Augustana College, Sioux Falls, SD

Academic Interests

Diet and exercise and its effects on MS
Spasticity management
Clinical drug trials
Neuroimaging and demylination

Expertise

Multiple Sclerosis
Spasticity
Baclofen Pump Programming
Botulinum Toxin Injections

Academic Appointments

2014-present: Associate Professor of Neurological Sciences, University of Vermont College of Medicine

2008-2014:  Assistant Professor of Neurology, University of Vermont College of Medicine

Clinical Appointments

2011-Present:  Director, MS Center of Northern New England, Fletcher Allen Health Care/University of Vermont
2011-Present:  Director, MS/Neuroimmunology Fellowship at Fletcher Allen Health Care/University of Vermont

Board Certification

2007:  Board certification in Neurology, American Board of Psychiatry & Neurology

Licensure

2006-present:  Medical Licensure, State of Vermont

Awards and Honors

2011:  Stanley F. Waterman Lecturer, Keynote speaker for Greater New England MS Chapter meeting and recognized for commitment to scientific research in the field of MS.
2005:  American Headache Society (AHS) Scholarship, Awarded to attend the annual Headache Symposium.
2005:  Golden Apple Award, Recognition of outstanding teaching in neurology, Fletcher Allen Health Care.
2004:  Arnold P. Gold Foundation Humanism in Medicine Award, Nominated by the University of Vermont College of Medicine Class of 2005 and 2004 for humanism and excellence in teaching.
2003:  Outstanding Resident Award - Emergency Department, Fletcher Allen Health Care.
2001-2002:  James H. Hoskins Memorial Scholarship, Awarded annually by the University of South Dakota School of Medicine.
2000-2001:  Atkinson-Ohlmacher Scholarship, Awarded annually by the University of South Dakota School of Medicine for academic achievement.
1999-2000:  Constantine W. Fleveares, M.D. Sophomore Award, Scholarship awarded annually by the University of South Dakota School of Medicine for academic achievement.
1998-1999:  Dr. Roy S. & Clara E. Hubbs Memorial Scholarship, Awarded annually by the University of South Dakota School of Medicine.

Professional Activities

2003-Present:  Member, Northern New England Neurological Society
2003-Present:  Member, American Academy of Neurology
2005-Present:  Member, American Headache Society

Research Grants

November 2011-Present: A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study to Evaluate the Efficacy and Safety of Ocrelizumab in Comparison to Interferon beta-1a (Rebif ®) In Patients with Relapsing Remitting Multiple Sclerosis. Genentech, Inc. /Roche. Role: Site PI.
January 2011-Present:  Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Two doses of Oral Dalfampridine Extended Release Tablets (5 mg and 10 mg) Twice Daily in Patients With Multiple Sclerosis. Acorda Therapeutics. Role: Site PI.
January 2011-Present: JCV Antibody Program in Patients with Relapsing Multiple Sclerosis Receiving or Considering Treatment with Tysabri: STRATIFY. Role: Site PI.
September 2010-Present:  A Double-blind, randomized, multicenter, placebo-controlled, parallel group study comparing the efficacy and safety of 0.5 mg FTY 720 administered orally once daily versus placebo in patients with primary progressive Multiple Sclerosis. Role: Site PI.
November 2010-Present:  A Randomized, Multicenter, Placebo-Controlled and Active Reference (Glatiramer Acetate) Comparison Study To Evaluate the Efficacy and Safety of BG00012 in Subjects with Relapsing-Remitting Multiple Sclerosis. Role: Site PI.
November 2010-Present:  Phase II, Multicenter, Randomized, Parallel-Group, Partially-Blinded, Placebo and Avonex Controlled Dose Finding Study to Evaluate the Efficacy, as measured by Brain MRI Lesions and Safety  of Two Dose Regimens of Ocrelizumab in Patients with Relapsing-Remitting Multiple Sclerosis. Role: Site PI
July 2006-Present:  A Multi-Center, Double-blind, Randomized Study Comparing the Combined Use of Interferon Beta 1a (Avonex) and Glatiramer Acetate (Copaxone) to Either Agent Alone in Patients with Relapsing-Remitting Multiple Sclerosis (Combi Rx-Phase III). NIH funded, grant held by Mount Sinai. H Panitch, Site PI. Role: Site Sub-investigator.

Publications

Attarian H, Applebee G, Applebee A, Wang BingXia, Clark M, McCormick B, Salzman E, Schuman C.  Effect of Eszopiclone on Sleep Disturbances and Daytime Fatigue in Multiple Sclerosis Patients. Int J MS Care 2011; 13:84-90.

Panitch H, Applebee A. Treatment of Walking Impairment In Multiple Sclerosis: An Unmet Need for a Disease-Specific Disability. Expert Opinion on Pharmacotherapy Jul 2011, Vol. 12, No. 10:1511-1521.

Applebee A, Panitch H.  Early Stage and Long Term Treatment of Multiple Sclerosis with Interferon Beta.  Biologics: Targets & Therapy 2009; 3:257-271.

Applebee A, Ramundo M, Kirkpatrick BD, Fries T, Panitch H. Intramedullary Abscess in a Healthy Woman.  Neurology 2007; 68: 1230.

Applebee AM, Shapiro RE. Cluster Migraine: Does It  Exist? Curr Pain Headache Rep 2007; 11: 154-157.

To see more of Dr. Applebee's publications, please visit PubMed.